What is Humanetics Corp?
Humanetics Corporation is a biotechnology firm dedicated to pioneering novel therapeutic strategies for solid tumor cancers. Their primary focus is on enhancing patient outcomes during radiation therapy, with their lead product, BIO 300, showing promise in improving treatment efficacy. Beyond oncology, the company is exploring applications for inflammatory lung diseases and developing medical countermeasures against radiation injuries, positioning itself as a key player in both advanced cancer care and defense against nuclear threats. The company targets oncology patients, healthcare providers, and defense sectors, aiming to protect civilians and military personnel.
How much funding has Humanetics Corp raised?
Humanetics Corp has raised a total of $125K across 1 funding round:
Debt
$125K
Debt (2021): $125K with participation from PPP
Key Investors in Humanetics Corp
PPP
Public-Private Partnership
What's next for Humanetics Corp?
With a substantial large-scale late-stage funding context, Humanetics Corp is poised for significant expansion and clinical advancement. The recent major strategic investment suggests strong confidence from stakeholders in the company's pipeline, particularly its BIO 300 product. This capital infusion is expected to accelerate ongoing clinical trials, support regulatory submissions, and potentially broaden the therapeutic applications of their innovations. The company's dual focus on improving cancer treatment and developing radiation countermeasures indicates a robust strategy for long-term growth and market penetration in both healthcare and defense industries.
See full Humanetics Corp company page
